Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03116997 · ClinicalTrials.gov registry record · Phase 3
Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant
A Phase 3 study of Surgery, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 201
- Enrollment target
- 4
- Study locations
NCT03116997: Completed Phase 3 study of Surgery, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03116997 is a Phase 3 study of Surgery that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 201 participants, below the 52,850-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03116997, a Phase 3 study of Surgery, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 201 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to compare two different medications (neostigmine/glycopyrrolate and sugammadex) to see if one drug improves patient comfort regarding the return of muscle strength after surgery.
Primary Outcome
Determine whether SUG, as compared to NEO decreases time for patients to be ready for discharge from the PACU post-surgery.
Conditions Studied
Interventions
- DRUG Sugammadex
- DRUG Neostigmine+glycopyrrolate
Study Locations (4)
New York
- Memorial Sloan Kettering Commack - Commack
- Memoral Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
New Jersey
- Memoral Sloan Kettering Basking Ridge - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2017-04-07 |
| Est. Completion | 2022-03-03 |
| Phase | Phase 3 |
What the finished NCT03116997 record still lists
NCT03116997 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, below the 52,850-participant average among 120 other Surgery trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Surgery appearing as the primary indexed condition, and to 2 interventions - of which Sugammadex is the first listed.
NCT03116997 reports a single indexed study location in New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03116997 about?
NCT03116997 is a clinical study titled "Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant". The purpose of this study is to compare two different medications (neostigmine/glycopyrrolate and sugammadex) to see if one drug improves patient comfort regarding the return of muscle strength after surgery.
What is the current status of trial NCT03116997?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 201 participants. The study started on 2017-04-07. Estimated completion is 2022-03-03.
What conditions does trial NCT03116997 study?
This clinical trial studies the following conditions: Surgery.
What interventions are being tested in trial NCT03116997?
The interventions under investigation include: Sugammadex (DRUG), Neostigmine+glycopyrrolate (DRUG).
Who is sponsoring clinical trial NCT03116997?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03116997 being conducted?
This trial has 4 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgery
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03116997's enrollment target sits among peer trials
201 41st of 120 higher than 80 of 120 other Surgery trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Surgery trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NO During CPB in Neonates to Reduce Risk of AKI
RECRUITING · Phase 3
-
Sentinel Node Biopsy in Endometrial Cancer
RECRUITING · Phase 3
-
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
RECRUITING · Phase 3
-
The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial
ACTIVE NOT RECRUITING · Phase 3
-
Evaluating Outcomes in Cardiac Surgery Patients Who Receive Sugammadex vs. Placebo
ACTIVE NOT RECRUITING · Phase 3
-
Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI